Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer
- Authors
- Park, IH[Park, I. H.]; Im, SA[Im, S-A]; Jung, KH[Jung, K. H.]; Sohn, JH[Sohn, J. H.]; Park, YH[Park, Y. H.]; Park, KH[Park, K-H]; Nam, BH[Nam, B-H]; Kim, JH[Kim, J. H.]; Kim, HJ[Kim, H-J]; Lee, S[Lee, S.]; Kim, TY[Kim, T-Y]; Lee, KH[Lee, K-H]; Kim, SB[Kim, S-B]; Lee, KS[Lee, K. S.]; Ro, J[Ro, J.]
- Issue Date
- Feb-2017
- Publisher
- AMER ASSOC CANCER RESEARCH
- Citation
- CANCER RESEARCH, v.77
- Indexed
- SCIE
SCOPUS
- Journal Title
- CANCER RESEARCH
- Volume
- 77
- ISSN
- 0008-5472
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.